Post Menopausal Osteoporosis-Pipeline Review, H1 2017

Post Menopausal Osteoporosis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9264IDB
  • |
  • Pages: 73
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Post Menopausal Osteoporosis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis-Pipeline Review, H1 2017, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Preclinical stages are 4, 1 and 6 respectively.

Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Post Menopausal Osteoporosis-Overview

Post Menopausal Osteoporosis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Post Menopausal Osteoporosis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Post Menopausal Osteoporosis-Companies Involved in Therapeutics Development

Amgen Inc

Enteris BioPharma Inc

Intas Pharmaceuticals Ltd

Ipsen SA

Ligand Pharmaceuticals Inc

Lupin Ltd

NIBEC

Oncobiologics Inc

Paras Biopharmaceuticals Finland Oy

Post Menopausal Osteoporosis-Drug Profiles

abaloparatide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

calcitonin DR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lasofoxifene tartrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romosozumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide for Obesity and Post Menopausal Osteoporosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teriparatide biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Post Menopausal Osteoporosis-Dormant Projects

Post Menopausal Osteoporosis-Discontinued Products

Post Menopausal Osteoporosis-Product Development Milestones

Featured News & Press Releases

Apr 28, 2017: FDA Approves Radius Healths TYMLOS (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture

Apr 07, 2017: Osteoporosis drug found safe in long-term trial

Apr 03, 2017: New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies

Apr 01, 2017: Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY (romosozumab)

Mar 10, 2017: Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC

Feb 01, 2017: Mayo Clinic Proceedings Publishes Positive Results from the ACTIVExtend Clinical Trial of Abaloparatide-SC in Postmenopausal Women With Osteoporosis

Nov 07, 2016: Amgen To Present Data On Denosumab At ACR/ARHP 2016 Annual Meeting

Oct 19, 2016: Research Reveals How Novel Osteoporosis Drug Increases Bone Mass

Sep 26, 2016: Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab

Sep 19, 2016: Radius Presents Abaloparatide Transdermal Patch Development Program at American Society for Bone and Mineral Research 2016 Annual Meeting

Sep 18, 2016: Radius Announces Publication of Additional Positive Results from the Phase 3 ACTIVE Trial of Abaloparatide-SC in JBMR

Sep 18, 2016: Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis

Sep 14, 2016: Amgen to present romosozumab at Investor Call

Sep 07, 2016: UCB to present results from Phase 3 FRAME Study at the American Society for Bone and Mineral Research Annual Meeting

Aug 16, 2016: JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women With Osteoporosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Post Menopausal Osteoporosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Post Menopausal Osteoporosis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Post Menopausal Osteoporosis-Pipeline by Amgen Inc, H1 2017

Post Menopausal Osteoporosis-Pipeline by Enteris BioPharma Inc, H1 2017

Post Menopausal Osteoporosis-Pipeline by Intas Pharmaceuticals Ltd, H1 2017

Post Menopausal Osteoporosis-Pipeline by Ipsen SA, H1 2017

Post Menopausal Osteoporosis-Pipeline by Ligand Pharmaceuticals Inc, H1 2017

Post Menopausal Osteoporosis-Pipeline by Lupin Ltd, H1 2017

Post Menopausal Osteoporosis-Pipeline by NIBEC, H1 2017

Post Menopausal Osteoporosis-Pipeline by Oncobiologics Inc, H1 2017

Post Menopausal Osteoporosis-Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017

Post Menopausal Osteoporosis-Dormant Projects, H1 2017

Post Menopausal Osteoporosis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Amgen Inc, Enteris BioPharma Inc, Intas Pharmaceuticals Ltd, Ipsen SA, Ligand Pharmaceuticals Inc, Lupin Ltd, NIBEC, Oncobiologics Inc, Paras Biopharmaceuticals Finland Oy

Post Menopausal Osteoporosis Therapeutic Products under Development, Key Players in Post Menopausal Osteoporosis Therapeutics, Post Menopausal Osteoporosis Pipeline Overview, Post Menopausal Osteoporosis Pipeline, Post Menopausal Osteoporosis Pipeline Assessment

select a license
Single User License
USD 2000 INR 143800
Site License
USD 4000 INR 287600
Corporate User License
USD 6000 INR 431400

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com